Skip to main content
Midas Edge

PLUS THERAPEUTICS, INC.

For the period ended Sep 30, 2025. Filed Oct 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 30, 2025

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity/(Deficit

(UNAUDITED) (In thousands, except share data)

Convertible · Additional · Total
preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’
Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity
Balance at December 31, 20231,952$—4,522,656$5(78,559)$(126)$479,274$(480,501)$(1,348)
Stock-based compensation——————146—146
Purchase of treasury stock————(179,866)(374)——(374)
Net loss———————(3,261)(3,261)
Balance at March 31, 20241,952$—4,522,656$5(258,425)$(500)$479,420$(483,762)$(4,837)
Issuance of common stock——1,439,9881————1
Stock-based compensation——————151—151
Net loss———————(2,940)(2,940)
Balance at June 30, 20241,952$—5,962,644$6(258,425)$(500)$479,571$(486,702)$(7,625)
Reclass of warrants to equity——————5,200—5,200
Stock-based compensation——————125—125
Exercise of pre-funded warrants——192,114——————
Net loss———————(2,874)(2,874)
Balance at September 30, 20241,952$—6,154,758$6(258,425)$(500)$484,896$(489,576)$(5,174)
Balance at December 31, 20241,952$—6,154,758$6(258,425)$(500)$485,024$(493,479)$(8,949)
Stock-based compensation——————148—148
Exercise of pre-funded warrants——6,535,7317——(7)——
Exercise of Series B Warrants from May 2024 PIPE——497,824———882—882
Exchange of warrants for notes payable——————(3,694)—(3,694)
Issuance of common stock, pre-funded warrants and warrants for debt repayment——4,069,7384——5,369—5,373
Net loss———————(17,401)(17,401)
Balance at March 31, 20251,952$—17,258,051$17(258,425)$(500)$487,722$(510,880)$(23,641)
Stock-based compensation——————152—152
Exercise or exchange of March 2025 Series A and B Warrants——56,277,03256——802—858
Exercise of pre-funded warrants——9,016,3499——(9)——
Cancellation of common stock——(300,000)——————
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs——10,187,00010——2,736—2,746
Reclassification of 2025 Series B warrant liability to equity——————10,967—10,967
Modification of warrants (Note 13)———6,801—6,801
Net income———————5,1515,151
Balance at June 30, 20251,952$—92,438,432$92(258,425)$(500)$509,171$(505,729)$3,034
Stock-based compensation——————527—527
Cancelled common stock——(3,472,740)(3)——3——
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs——34,388,49635——16,815—16,850
Investor fees pursuant to Support Letters (Note 13)——————(2,250)—(2,250)
Exercise of March 2025 Series B Warrants——741,840——————
Exercise of pre-funded warrants——7,767,9418——(8)——
Liability to investors pursuant to Letter Agreement (Note 13)——————(8,684)—(8,684)
Net loss———————(4,423)(4,423)
Balance at September 30, 20251,952$—131,863,969$132(258,425)$(500)$515,574$(510,152)$5,054
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.